Progressive Lipodystrophy

Back

Background

Lipodystrophy syndromes represent a group of rare, heterogeneous disorders characterized by progressive loss of fat tissue, mainly from the subcutaneous compartment and occasionally from visceral fat.[1] Subcutaneous loss of fat can occur as generalized or partial lipodystrophy; the latter is more common. Progressive lipodystrophy is the most common type of partial lipodystrophy.

The other types, such as the Kobberling-Dunnigan variety or the familial mandibuloacral dysplasia syndrome, may be familial and tend to be associated with metabolic anomalies such as glucose intolerance and hypertriglyceridemia. Nakajo-Nishimura syndrome is an inherited inflammatory disease that usually begins in early infancy with a perniolike rash, periodic high fever, and nodular erythemalike eruptions, with gradually progressive partial lipoatrophy of the upper body, mainly the face and the upper extremities.[2] Acquired partial lipodystrophy is a rare condition of unknown etiology characterized by progressive loss of fat of the face, neck, trunk, and upper extremities beginning during childhood and is more common in girls.[3]

Progressive lipodystrophy is a rare condition that typically affects children and young adults. The first case was described by Mitchell in 1886,[4] and later cases were described by Barraquer in 1907 and Simons in 1911. The onset is usually insidious with the slow, progressive disappearance of subcutaneous fat involving the upper half of the body. The predictive progression of the disease from the face to the neck, upper extremities, and trunk (sparing the buttocks and lower limbs) is characteristic. Associated hypocomplementemia, glomerulonephritis, and autoimmune disorders are frequently present in some patients. However, some forms of partial lipodystrophy in children do not seem to fit the diagnostic criteria for any of the established lipodystrophy subset.[5]

Pathophysiology

The etiology of this condition is obscure. Lipodystrophy is often associated with glomerulonephritis, low C3 serum complement levels, and the presence of a C3 nephritic factor. C3 nephritic factor is a serum immunoglobulin G that interacts with the C3bBb alternative pathway convertase to activate C3.

C3 nephritic factor induces the lysis of adipocytes that secrete adipsin, a product identical to complement factor D. The distribution of the lipoatrophy is postulated to be dictated by the variable amounts of adipsin secreted by the adipocytes at different locations.

Human PTRF mutations may cause secondary deficiency of caveolins, resulting in generalized lipodystrophy in association with in muscular dystrophy.[6]

Dunnigan-type familial partial lipodystrophy was linked with heterozygous R482W mutation in the LMNA gene in an analysis of 3 women from one family.[7]

Epidemiology

Frequency

International

Progressive lipodystrophy is rare, with fewer than 200 cases reported in the world literature since the first case was reported in 1885.[8]

Mortality/Morbidity

Acquired progressive lipodystrophy is a nonfatal condition, but it is frequently associated with mesangiocapillary glomerulonephritis, which can lead to renal insufficiency. In pregnancy, more severe renal disease is associated with a risk of intrauterine growth retardation, prematurity, and fetal death.[9] Associated autoimmune disorders are also present in some patients, including systemic lupus erythematosus and dermatomyositis.

Race

No racial predilection is reported for progressive lipodystrophy.

Sex

Progressive lipodystrophy is 4-5 times more common in women than in men. Of patients with progressive lipodystrophy, 80% are females. The accumulation of fat in the buttocks and lower limbs occurs almost exclusively in females. Males who are affected usually have lipoatrophy without lower body hypertrophy.

Age

Progressive lipodystrophy typically starts in individuals aged 0-20 years, with most cases starting before individuals are aged 15 years. Progressive lipodystrophy tends to develop earlier in most male patients compared with female patients.

History

Patients with progressive lipodystrophy are born healthy with a normal appearance and fat distribution. In individuals aged 0-20 years, progressive loss of fat, which first involves the face, spreads distally to the neck, arms, and trunk; the lower part of the body is usually spared.

Physical

Because of the insidious onset and slow progression of progressive lipodystrophy, most patients present when the disease is in an advanced stage. Advanced cases have a characteristic physical appearance.

The face appears cachectic. Buccal fat pads are absent, resulting in a prominent zygoma and chin. The temples and cheeks are hollowed, causing a cadaverous appearance. The eyes are deeply sunken due to the loss of periorbital fat. The face is heavily lined, creating numerous wrinkles lying over the cheeks, which causes the appearance of premature senility. The scalp, hair, and other facial areas are generally unaffected. However, centrifugal lipodystrophy has been described in a child with progressive arch–form alopecia. The alopecia continuously extended for a decade, after which expansion ceased, leaving a linear nonhairy patch.[10]

Frequently, the breasts are underdeveloped, with a firm, nodular feel. The arms and shoulders have a clear, well-demarcated outline of muscles below the skin, which gives the false impression of increased muscularity.

The area of fat loss is sharply demarcated at a level above the thighs; the lower extremities are spared. The uninvolved lower part of the body appears obese when contrasted with the upper, thin area. In female patients, excessive fat may develop on the legs and buttocks after puberty.

The overlying skin itself is normal in color, elasticity, and texture. No muscular hypertrophy is noted.

Causes

No specific cause or risk factor has been elucidated for progressive lipodystrophy. Some reports have shown a correlation of progressive lipodystrophy with prior acute viral or bacterial infection. Acquired partial lipodystrophy (Barraquer-Simons syndrome) usually follows acute febrile illness; it can rarely be seen in association with varicella.[11]

Laboratory Studies

Urinalysis may be helpful in progressive lipodystrophy. Approximately one third of patients with this condition have some degree of glomerulonephritis, and, if hypocomplementemia is present, the risk is higher. Manifestations of glomerulonephritis range from asymptomatic proteinuria to a nephrotic syndrome and renal insufficiency.

Baseline creatinine and blood urea nitrogen studies, as well as urine studies, should be performed to detect proteinuria and hematuria.

A CBC count should be obtained. Normochromic normocytic anemia is often present.

Immune studies can be ordered. Immune studies may be needed to identify patients with associated immune disorders, particularly if the diagnosis of partial lipodystrophy is made at a younger age. The presence of serum antinuclear antibodies and anti–double-stranded DNA antibodies has been reported in some patients.

Complement levels may be determined. The most common laboratory abnormality in patients with progressive lipodystrophy is a low complement level. Hypocomplementemia is characterized by a low C3 complement level, a normal C4 level, and the presence of C3 nephritic factor.

Lipid studies may be performed. Hypertriglyceridemia secondary to nephrotic syndrome may be present in some patients.

Imaging Studies

Head MRIs show evidence of fat loss in progressive lipodystrophy patients.

Other Tests

Immunofluorescence studies in progressive lipodystrophy patients show deposits of C3 in a granular pattern in the basement membranes.

Procedures

Skin biopsy findings confirm the progressive lipodystrophy diagnosis. Kidney biopsy is required if a glomerulonephritis is associated with the progressive lipodystrophy.

Histologic Findings

Cutaneous biopsy in progressive lipodystrophy reveals a reduction or absence of subcutaneous fat in affected areas. Subcutaneous fat cells are decreased in number.

Traces of adipose tissue may be found around hair follicles and sebaceous glands. The dermis and epidermis are normal.

Renal biopsy findings are characterized by a membranoproliferative glomerulonephritis with a proliferation of mesangial cells and matrix, as well as thickening of the basement membranes by amorphous electron-dense deposits.

Immunofluorescence studies show deposits of C3 in a granular pattern in the basement membranes.

Medical Care

No specific treatment for progressive lipodystrophy is effective. Symptomatic therapy should be prescribed as necessary for the treatment of renal complications and associated autoimmune disorders in progressive lipodystrophy patients.

Surgical Care

Various surgical techniques have been adopted through the years in an effort to improve progressive lipodystrophy patients’ facial appearance.[14, 15] Dermal-fat grafts from the gluteal region, temporal muscle flaps, silicone-filling material, and subcutaneous injections of fat from unaffected areas have been used with variable results. A novel surgical technique consists of a 1-stage transfer of 2 paddles of thoracodorsal artery perforator flap with 1 pair of vascular anastomoses for simultaneous restoration of bilateral facial atrophy.[3] It may be useful in selected patients for the reconstruction of bilateral facial atrophy.

Consultations

Referral to a nephrologist or an internist may be warranted for progressive lipodystrophy patients with severe nephropathy and those with associated autoimmune diseases.

Diet

Hyperalimentation can result in the excessive accumulation of fat in an unaffected area with no improvement on dystrophic areas.

Medication Summary

No medical treatment for progressive partial lipodystrophy has proven effective. However, leptin replacement in lipodystrophy patients may lead to significant and sustained improvements in glycemic control and dyslipidemia and thus be effective in the various forms of lipodystrophy.[16]

Symptomatic therapy may be indicated in progressive lipodystrophy patients with severe nephropathy or associated immune disorders.

Further Inpatient Care

Renal and immunologic disturbances may warrant inpatient care at times.

During pregnancy, the health status of the fetus should be ascertained with modalities such as an electronic fetal monitor. Fetal health assessment is particularly important during the third trimester to reduce the risk of intrauterine fetal death associated with progressive lipodystrophy.

Further Outpatient Care

Note the following:

Inpatient & Outpatient Medications

No inpatient or outpatient medications are specific for lipodystrophy. Symptomatic therapy may be required for patients with nephropathy or associated immune disorders.

Complications

Note the following complications:

Prognosis

The prognosis for progressive lipodystrophy is correlated with the renal complications and the onset of renal failure.

Author

Robert A Schwartz, MD, MPH, Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Coauthor(s)

Geover Fernandez, MD, FAAD, Staff Physician, Department of Dermatology, University of Medicine and Dentistry New Jersey, New Jersey Medical School

Disclosure: Nothing to disclose.

Isabelle Thomas, MD, Associate Professor, Department of Dermatology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School; Chief of Dermatology Service, Veterans Affairs Medical Center of East Orange

Disclosure: Nothing to disclose.

Specialty Editors

David P Fivenson, MD, Associate Director, St Joseph Mercy Hospital Dermatology Program, Ann Arbor, Michigan

Disclosure: Nothing to disclose.

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Disclosure: Nothing to disclose.

Lester F Libow, MD, Dermatopathologist, South Texas Dermatopathology Laboratory

Disclosure: Nothing to disclose.

Catherine M Quirk, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

References

  1. Herranz P, de Lucas R, Perez-España L, Mayor M. Lipodystrophy syndromes. Dermatol Clin. Oct 2008;26(4):569-78, ix. [View Abstract]
  2. Kanazawa N. Nakajo-Nishimura Syndrome: An Autoinflammatory Disorder Showing Pernio-Like Rashes and Progressive Partial Lipodystrophy. Allergol Int. Mar 25 2012;0(0):[View Abstract]
  3. Okazaki M, Tanaka K, Kodaira S, Homma T, Miyashita H. One-Stage Transfer of 2 Paddles of Thoracodorsal Artery Perforator Flap With 1 Pair of Vascular Anastomoses for Barraquer-Simons Syndrome. J Craniofac Surg. May 4 2012;[View Abstract]
  4. Mitchell SW. Singular case of absence of adipose matter in the upper half of the body. Am J Med Sci. 1885;90:105-106.
  5. Maffeis L, Vercellesi P, Corona F, Forzenigo L, Gelmetti C. Acquired acral lipodystrophy in a 6-year-old girl. Pediatr Dermatol. Sep-Oct 2009;26(5):566-8. [View Abstract]
  6. de Haan W. Lipodystrophy and muscular dystrophy caused by PTRF mutations. Clin Genet. May 2010;77(5):436-7. [View Abstract]
  7. Nabrdalik K, Strózik A, Minkina-Pedras M, Jarosz-Chobot P, Mlynarski W, Grzeszczak W, et al. [Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene - case study of three women from one family]. Endokrynol Pol. 2013;64(4):306-11. [View Abstract]
  8. Ferrarini A, Milani D, Bottigelli M, Cagnoli G, Selicorni A. Two new cases of Barraquer-Simons syndrome. Am J Med Genet A. May 1 2004;126A(4):427-9. [View Abstract]
  9. Haxton MJ. Progressive partial lipodystrophy in association with intrauterine death and growth retardation. Am J Obstet Gynecol. Dec 1 1983;147(7):837-8. [View Abstract]
  10. Fukumoto D, Kubo Y, Saito M, Arase S. Centrifugal lipodystrophy of the scalp presenting with an arch-form alopecia: a 10-year follow-up observation. J Dermatol. Sep 2009;36(9):499-503. [View Abstract]
  11. Kurugol Z, Ulger Z, Berk O, Tugral O. Acquired partial lipodystrophy associated with varicella. Turk J Pediatr. Nov-Dec 2009;51(6):617-20. [View Abstract]
  12. Spranger S, Spranger M, Tasman AJ, Reith W, Voigtlander T, Voigtlander V. Barraquer-Simons syndrome (with sensorineural deafness): a contribution to the differential diagnosis of lipodystrophy syndromes. Am J Med Genet. Sep 5 1997;71(4):397-400. [View Abstract]
  13. Hagari Y, Sasaoka R, Nishiura S, Ishihara M, Mihara M, Shimao S. Centrifugal lipodystrophy of the face mimicking progressive lipodystrophy. Br J Dermatol. Oct 1992;127(4):407-10. [View Abstract]
  14. Coessens BC, Van Geertruyden JP. Simultaneous bilateral facial reconstruction of a Barraquer-Simons lipodystrophy with free TRAM flaps. Plast Reconstr Surg. Apr 1995;95(5):911-5. [View Abstract]
  15. Serra JM, Ballesteros A, Mesa F, Bazan A, Paloma V, Sanz J. Use of the temporal muscle flap in Barraquer-Simon's progressive lipodystrophy. Ann Plast Surg. Feb 1993;30(2):180-2. [View Abstract]
  16. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. Sep 2 2009;[View Abstract]
  17. Font J, Herrero C, Bosch X, Cervera R, Ingelmo M, Mascaro JM. Systemic lupus erythematosus in a patient with partial lipodystrophy. J Am Acad Dermatol. Feb 1990;22(2 Pt 2):337-40. [View Abstract]
  18. Quecedo E, Febrer I, Serrano G, Martinez-Aparicio A, Aliaga A. Partial lipodystrophy associated with juvenile dermatomyositis: report of two cases. Pediatr Dermatol. Nov-Dec 1996;13(6):477-82. [View Abstract]
  19. Fitch N, Tulandi T. Progressive partial lipodystrophy and third-trimester intrauterine fetal death. Am J Obstet Gynecol. May 1987;156(5):1195-6. [View Abstract]
  20. Greene AK. Lluis Barraquer-Roviralta (1855-1928): Spanish neurologist described progressive lipodystrophy. Plast Reconstr Surg. Jan 2001;107(1):158-62. [View Abstract]
  21. Halazonetis J. A case of progressive lipodystrophy. Barraquer-Simon's disease. Br J Oral Surg. Nov 1968;6(2):130-3. [View Abstract]
  22. Hegele RA, Cao H, Liu DM, Costain GA, Charlton-Menys V, Rodger NW. Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am J Hum Genet. Aug 2006;79(2):383-9. [View Abstract]
  23. Ketterings C. Lipodystrophy and its treatment. Ann Plast Surg. Dec 1988;21(6):536-43. [View Abstract]
  24. Levy Y, George J, Yona E, Shoenfeld Y. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res. Aug 1998;18(1):55-60. [View Abstract]
  25. Mathieson PW, Wurzner R, Oliveria DB, Lachmann PJ, Peters DK. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med. Jun 1 1993;177(6):1827-31. [View Abstract]
  26. McNeill AD. Progressive lipodystrophy. Br J Surg. Mar 1966;53(3):216-8. [View Abstract]
  27. Perrot H, Delaup JP, Chouvet B. [Barraquer and Simons lipodystrophy. Complement anomalies and cutaneous leukocytoclasic vasculitis]. Ann Dermatol Venereol. 1987;114(9):1083-91. [View Abstract]
  28. [Guideline] Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDS. Aug 2001;15(8):411-23. [View Abstract]
  29. Pope E, Janson A, Khambalia A, Feldman B. Childhood acquired lipodystrophy: a retrospective study. J Am Acad Dermatol. Dec 2006;55(6):947-50. [View Abstract]
  30. Requena Caballero C, Angel Navarro Mira M, Bosch IF, Bauxauli JM, Aliaga Boniche A. Barraquer-Simons lipodystrophy associated with antiphospholipid syndrome. J Am Acad Dermatol. Oct 2003;49(4):768-9. [View Abstract]
  31. Rifkind BM, Boyle JA, Gale M. Blood lipid levels, thyroid status, and glucose tolerance in progressive partial lipodystrophy. J Clin Pathol. Jan 1967;20(1):52-5. [View Abstract]
  32. Sissons JG, West RJ, Fallows J, et al. The complement abnormalities of lipodystrophy. N Engl J Med. Feb 26 1976;294(9):461-5. [View Abstract]
  33. Smak Gregoor PJ, van Bommel EF, Ketterings C, van Saase JL, Kramer P. Progressive lipodystrophy, a diagnosis at a glance. Nephrol Dial Transplant. Feb 1998;13(2):507-9. [View Abstract]
  34. Sonnino M, Ribuffo D, Piovano L, Cigna E, Scuderi N. [Nonprogressive, late-onset atrophy of the cheek]. Minerva Chir. Dec 2000;55(12):881-5. [View Abstract]
  35. Van Etten E, Branisteanu DD, Overbergh L, Bouillon R, Verstuyf A, Mathieu C. Combination of a 1,25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone. Apr 2003;32(4):397-404. [View Abstract]
  36. Walport MJ, Davies KA, Botto M, et al. C3 nephritic factor and SLE: report of four cases and review of the literature. QJM. Oct 1994;87(10):609-15. [View Abstract]
  37. Williams DG. C3 nephritic factor and mesangiocapillary glomerulonephritis. Pediatr Nephrol. Feb 1997;11(1):96-8. [View Abstract]
  38. Yavuz S, Acarturk TO. Acquired partial lipodystrophy with C3 hypocomplementemia and antiphospholipid and anticardiolipin antibodies. Pediatr Dermatol. Sep-Oct 2010;27(5):504-8. [View Abstract]